A 62-year-old postmenopausal woman presents with a T-score of −2.8 on DEXA scan of the lumbar spine. She has no prior fragility fractures, no contraindications to bisphosphonates, and normal renal function (eGFR 78 mL/min/1.73 m²). She is currently on calcium 1000 mg and vitamin D 800 IU daily. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient meets diagnostic criteria for osteoporosis (T-score ≤ −2.5) without prior fragility fractures. She is a postmenopausal woman with no contraindications to pharmacotherapy. ## Management Algorithm for Osteoporosis ```mermaid flowchart TD A[Osteoporosis diagnosed on DEXA]:::outcome --> B{Prior fragility fracture?}:::decision B -->|Yes| C[High-risk: first-line bisphosphonate]:::action B -->|No| D{T-score ≤ −2.5 + risk factors?}:::decision D -->|Yes| E[Consider pharmacotherapy]:::action D -->|No| F[Reassess in 1-2 years]:::action E --> G{Renal function adequate?}:::decision G -->|eGFR ≥ 30| H[Bisphosphonate: alendronate or risedronate]:::action G -->|eGFR < 30| I[Denosumab or teriparatide]:::action H --> J[Counsel on dosing, monitoring]:::action ``` ## Key Point: **Bisphosphonates (alendronate, risedronate) are first-line agents** for postmenopausal osteoporosis without prior fracture, provided renal function is adequate (eGFR ≥ 30 mL/min/1.73 m²). ## High-Yield Facts - **Alendronate 70 mg weekly** is the standard starting dose; equivalent to 10 mg daily - Requires upright posture for 30 minutes post-dose and empty stomach - Reduces vertebral and hip fracture risk by ~50% over 3 years - This patient's eGFR of 78 is well above the threshold for safe use ## Clinical Pearl: **Teriparatide (PTH analog) is reserved for:** - Severe osteoporosis (T-score < −3) - Prior fragility fracture (especially vertebral) - Failure or intolerance of bisphosphonates - Not first-line in this scenario ## Why Calcium and Vitamin D Alone Are Insufficient While she is on appropriate supplementation, a T-score of −2.8 in a postmenopausal woman warrants pharmacotherapy to reduce fracture risk. Supplementation alone does not reverse bone loss at this magnitude. ## Monitoring After Initiation - Repeat DEXA in 2 years (not 6 months) - Monitor for atypical femoral fractures and osteonecrosis of jaw (rare with oral bisphosphonates) - Assess adherence and GI tolerance [cite:Harrison 21e Ch 405]